197 related articles for article (PubMed ID: 27774462)
1. One more stem cell niche: how the sensitivity of chronic myeloid leukemia cells to imatinib mesylate is modulated within a "hypoxic" environment.
Rovida E; Marzi I; Cipolleschi MG; Dello Sbarba P
Hypoxia (Auckl); 2014; 2():1-10. PubMed ID: 27774462
[TBL] [Abstract][Full Text] [Related]
2. The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy.
Rovida E; Peppicelli S; Bono S; Bianchini F; Tusa I; Cheloni G; Marzi I; Cipolleschi MG; Calorini L; Sbarba PD
Cell Cycle; 2014; 13(20):3169-75. PubMed ID: 25485495
[TBL] [Abstract][Full Text] [Related]
3. Imatinib-mesylate enhances the maintenance of chronic myeloid leukemia stem cell potential in the absence of glucose.
Bono S; Dello Sbarba P; Lulli M
Stem Cell Res; 2018 Apr; 28():33-38. PubMed ID: 29414416
[TBL] [Abstract][Full Text] [Related]
4. The Culture Repopulation Ability (CRA) Assay and Incubation in Low Oxygen to Test Antileukemic Drugs on Imatinib-Resistant CML Stem-Like Cells.
Cheloni G; Tanturli M
Methods Mol Biol; 2016; 1465():73-85. PubMed ID: 27581140
[TBL] [Abstract][Full Text] [Related]
5. Glutamine Availability Controls BCR/Abl Protein Expression and Functional Phenotype of Chronic Myeloid Leukemia Cells Endowed with Stem/Progenitor Cell Potential.
Poteti M; Menegazzi G; Peppicelli S; Tusa I; Cheloni G; Silvano A; Mancini C; Biagioni A; Tubita A; Mazure NM; Lulli M; Rovida E; Dello Sbarba P
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503182
[TBL] [Abstract][Full Text] [Related]
6. Chronic Myeloid Leukemia and Hepatoblastoma: Two Cancer Models to Link Metabolism to Stem Cells.
Cipolleschi MG; Marzi I; Rovida E; Dello Sbarba P
Front Oncol; 2016; 6():95. PubMed ID: 27148487
[TBL] [Abstract][Full Text] [Related]
7. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
Jiang X; Saw KM; Eaves A; Eaves C
J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736
[TBL] [Abstract][Full Text] [Related]
8. Chemokines as a Conductor of Bone Marrow Microenvironment in Chronic Myeloid Leukemia.
Mukaida N; Tanabe Y; Baba T
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28829353
[TBL] [Abstract][Full Text] [Related]
9. Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells.
Ma L; Pak ML; Ou J; Yu J; St Louis P; Shan Y; Hutchinson L; Li S; Brehm MA; Zhu LJ; Green MR
Proc Natl Acad Sci U S A; 2019 May; 116(21):10482-10487. PubMed ID: 31068472
[TBL] [Abstract][Full Text] [Related]
10. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
11. Characterization of cancer stem cells in chronic myeloid leukaemia.
Jørgensen HG; Holyoake TL
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
[TBL] [Abstract][Full Text] [Related]
12. Different BCR/Abl protein suppression patterns as a converging trait of chronic myeloid leukemia cell adaptation to energy restriction.
Bono S; Lulli M; D'Agostino VG; Di Gesualdo F; Loffredo R; Cipolleschi MG; Provenzani A; Rovida E; Dello Sbarba P
Oncotarget; 2016 Dec; 7(51):84810-84825. PubMed ID: 27852045
[TBL] [Abstract][Full Text] [Related]
13. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.
Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Carter BZ; Wang X; Shi X; Liu J
J Hematol Oncol; 2016 Nov; 9(1):129. PubMed ID: 27884201
[TBL] [Abstract][Full Text] [Related]
14. New strategies in controlling drug resistance in chronic myeloid leukemia.
Frame D
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S16-21. PubMed ID: 18056927
[TBL] [Abstract][Full Text] [Related]
15. Chronic myelogenous leukemia: molecular and cellular aspects.
Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
[TBL] [Abstract][Full Text] [Related]
16. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
17. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
18. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.
Gordon MK; Sher D; Karrison T; Kebriaei P; Chuang K; Zhang Y; McDonnell D; Artz A; Godley L; Odenike O; Rich E; Michaelis L; Thirman MJ; Wickrema A; van Besien K; Larson RA; Stock W
Leuk Lymphoma; 2008 Mar; 49(3):531-7. PubMed ID: 18297531
[TBL] [Abstract][Full Text] [Related]
19. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
20. BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients.
Levescot A; Flamant S; Basbous S; Jacomet F; Féraud O; Anne Bourgeois E; Bonnet ML; Giraud C; Roy L; Barra A; Chomel JC; Turhan A; Guilhot F; Girard JP; Gombert JM; Herbelin A
Cancer Res; 2014 May; 74(10):2669-76. PubMed ID: 24675360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
